Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* infection.
## Primary Indications
Eradication of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
**Standard Regimen:**
* **Lansoprazole:** 30 mg orally twice daily for 10-14 days.
* **Amoxicillin:** 1 gram orally twice daily for 10-14 days.
* **Clarithromycin:** 500 mg orally twice daily for 10-14 days.
**Note:** Dosing duration and specific regimens may vary based on local resistance patterns and clinical guidelines.
## Pediatric Dosing
Dosing in pediatric patients is not well-established for this combination product. Individual components may have pediatric dosing recommendations, but this specific combination product is generally not recommended for children. Consult pediatric infectious disease specialists for guidance.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required for lansoprazole or clarithromycin in mild to moderate renal impairment. However, amoxicillin may require dose adjustment in severe renal impairment (CrCl < 30 mL/min). Consult specific guidelines for amoxicillin.
* **Hepatic Impairment:** No dose adjustment is typically required for amoxicillin. Lansoprazole and clarithromycin may require caution or dose reduction in severe hepatic impairment.
## Contraindications
* Hypersensitivity to any of the components (lansoprazole, amoxicillin, clarithromycin) or other macrolides, penicillins, or proton pump inhibitors.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Use in patients with known or suspected ventricular dysfunction, QT prolongation, electrolyte disturbances, or concurrent use of other medications known to prolong the QT interval (due to clarithromycin).
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, headache, taste disturbance, rash.
* **Serious:** *Clostridium difficile*-associated diarrhea, severe allergic reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic dysfunction, QT prolongation, *C. difficile* colitis, fungal superinfections.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clarithromycin is a moderate inhibitor of CYP3A4. Concomitant use with drugs metabolized by CYP3A4 (e.g., warfarin, certain statins, certain antiarrhythmics, certain anticonvulsants) may increase their serum concentrations and risk of toxicity.
* **Warfarin:** Increased risk of bleeding. Monitor INR closely.
* **Digoxin:** Increased digoxin levels. Monitor digoxin levels.
* **Methotrexate:** Increased methotrexate levels.
* **Proton Pump Inhibitors:** May affect absorption of other drugs requiring acidic environments (e.g., ketoconazole, itraconazole, iron salts).
* **Amoxicillin:** May decrease the efficacy of oral contraceptives.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for development of *Clostridium difficile*-associated diarrhea.
* Monitor for efficacy of *H. pylori* eradication (e.g., urea breath test, stool antigen test, or biopsy results) typically 4-6 weeks after completion of therapy.
* Monitor liver function tests, especially in patients with pre-existing hepatic impairment.
* Monitor INR if co-administered with warfarin.
## Clinical Pearls
* Administer lansoprazole, amoxicillin, and clarithromycin together as a single regimen.
* Tablets should be swallowed whole and not crushed or chewed.
* Ensure patient compliance for the full 10-14 day course to maximize eradication rates.
* Advise patients to report any severe or persistent diarrhea, rash, or signs of allergic reaction immediately.
* Consider local antibiotic resistance patterns when selecting therapy.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to verify dosages and indications before patient use.
